EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Exploring the potential activity spectrum of two 5-nitroindazolinone prototypes on different Trypanosoma cruzi strains

CRISTINA FONSECA-BERZAL, PATRICIA BERNARDINO DA SILVA, CRISTIANE FRANÇA DA SILVA, MARIANE VASCONCELOS, MARCOS MEUSER BATISTA, JOSÉ A. ESCARIO, VICENTE J. ARÁN, ALICIA GÓMEZ-BARRIO, MARIA DE NAZARÉ C. SOEIRO

Parasitology Open · 2015

DOI: 10.1017/pao.2015.4 ↗
AbstractBibliografische Angaben

Abstract

SUMMARY In the present study, the potential activity of two 5-nitroindazole derivatives previously proposed as suitable antichagasic prototypes was further evaluated on diverse Trypanosoma cruzi strains belonging to two discrete typing units (DTUs) frequently associated with human infection (i.e. DTUs TcII and TcVI). The trypanocidal profile that both 2-benzyl-1-propyl (22) and 2-benzyl-1-butyl (24) derivatives achieved on Tulahuen amastigotes (IC 50 = 3·56 ± 0·99 and 6·31 ± 1·04 µ m , respectively) correlates with that of formerly obtained on CL Brener, corroborating an outstanding activity on DTU TcVI parasites. Moreover, a sequential screening on extracellular and intracellular stages of T. cruzi Y (DTU TcII) demonstrated also the effectiveness of 22 and 24 over this strain on a similar range of activity (IC 50 epimastigotes = 3·55 ± 0·47 and 7·92 ± 1·63 µ m , IC 50 amastigotes = 2·80 ± 0·46 and 9·02 ± 5·26 µ m , respectively). These results, supported by a lack of toxicity registered over either L929 fibroblasts or primary cultures of cardiomyocytes, confirm that 5-nitroindazolinones 22 and 24 display great selectivity on both drug-sensitive (CL and Tulahuen) and drug-moderately resistant (Y) T. cruzi strains, and therefore, represent an important outcome in the research of Chagas disease chemotherapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →